Alison Friedman, MD, MSc, is the director of Pediatric Hematology and Oncology. Developing a close relationship with her patients and their families through a challenging diagnosis and balancing motherhood with a career in medicine are the most rewarding aspects of her work.
Departments, Centers, & Programs:
55 Fruit Street
Boston, MA 02114-2696
Mass General/North Shore Center for Outpatient Care
104 Endicott Street
Danvers, MA 01923-3623
- MD, Dartmouth Medical School
- Residency, Dartmouth Hitchcock Medical Center
- Fellowship, The Johns Hopkins Hospital
American Board Certifications
- Pediatric Hematology-Oncology, American Board of Pediatrics
- Pediatrics, American Board of Pediatrics
Accepted Insurance Plans
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Alison Friedmann, MD has authored and reviewed many scholarly articles and book chapters in the area of childhood cancer. Her major research interests include: 1) Supportive care: Using an extensive blood bank database, she examined the importance of various risk factors in predicting bleeding in patients with low platelet counts to guide decisions around the use of platelet transfusion. At MGH, she developed a study for pediatric oncology patients with fever and neutropenia, the most common reason for unplanned hospitalization. The study identified patients at low risk of serious complications and provided an option for early discharge to a home antibiotic regimen. This strategy proved to be safe and greatly preferred by families. Building on this work, she successfully implemented a new clinical pathway for the outpatient management of low-risk fever and neutropenia, improving quality of life and reducing hospital stays. 2) Hematologic Malignancies: As a member of the Children's Oncology Group ALL committee, she helped coordinate a nationwide clinical trial for standard risk ALL, AALL0331, a trial that produced excellent outcomes while reducing therapy for the most favorable patients. She has also been a member of the St. Jude Pediatric Hodgkin lymphoma consortium, publishing the results of a major clinical trial in intermediate risk patients, and completing a project looking at the outcome of patients who suffer a relapse to focus on rational, optimal surveillance after treatment. 3) Radiation, sarcomas, and late effects: She has partnered with radiation oncology to study proton beam therapy's role in reducing late effects of therapy without compromising cure, and to develop strategies to reduce radiation exposure.
Alison Friedmann, MD has authored and reviewed many scholarly articles and book chapters in the area of childhood cancer. Here is a sampling of her publications. The extensive list can be found on PubMed.
Friedmann, AM, Weinstein HJ. The role of prognostic features in the treatment of childhood acute lymphoblastic leukemia. Oncologist. 2000;5(4):321-8.
Friedmann, AM, Weinstein HJ. The evolving standard of care for Hodgkin lymphoma. Journal of Pediatric Hematology Oncology. 2008; 30(2):121-3.
Friedmann, AM, Mariani J, Rupon JW, Talcott JA, Abrams AN, Weinstein HJ. Pilot test of a decision rule and implementation of an outpatient management strategy for low risk pediatric fever and neutropenia. In: Proceedings of the American Society of Hematology/Oncology Annual Meeting; 2015.
Friedmann, AM, Wolfson, JA, Hudson, MM, Weinstein HJ, Link MP, Billet A, Larse EC, Yock T, Donaldson SS, Marcus K, Krasin MJ, Howard SC, Metzger ML. Relapse after treatment of pediatric Hodgkin lymphoma: outcome and role of surveillance after end of therapy. Pediatric Blood Cancer. 2013; 60(9):1458-63.
Ladra MM, Szymonifka J, Mahajan A, Friedmann AM, Yeap BY, Goebel CP, MacDonlad SM, Grosshans D, Rodriguez-Galindo C, Marcus KH, Tarbell NJ, Yock TI. Preliminary Results of a Phase II Trial of Proton Radiotherapy for Pediatric Rhabdomyosarcoma. Journal of Clinical Oncology. 2014; 32:3762-3770.